Vertex PharmaceuticalsVRTXEarnings & Financial Report
Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England.
VRTX Q1 FY2026 Key Financial Metrics
Revenue
$3.0B
Gross Profit
$2.6B
Operating Profit
$1.1B
Net Profit
$1.0B
Gross Margin
86.8%
Operating Margin
38.1%
Net Margin
34.5%
YoY Growth
7.8%
EPS
$4.02
Vertex Pharmaceuticals Q1 FY2026 Financial Summary
Vertex Pharmaceuticals reported revenue of $3.0B (up 7.8% YoY) for Q1 FY2026, with a net profit of $1.0B (up 59.6% YoY) (34.5% margin). Cost of goods sold was $392.8M, operating expenses totaled $1.5B.
Key Financial Metrics
| Total Revenue | $3.0B |
|---|---|
| Net Profit | $1.0B |
| Gross Margin | 86.8% |
| Operating Margin | 38.1% |
| Report Period | Q1 FY2026 |
Revenue Breakdown
Vertex Pharmaceuticals Q1 FY2026 revenue of $3.0B breaks down across 5 segments, led by TRIKAFTA/KAFTRIO at $2.4B (78.8% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| TRIKAFTA/KAFTRIO | $2.4B | 78.8% |
| ALYFTREK | $424.4M | 14.2% |
| Other | $135.9M | 4.5% |
| CASGEVY | $42.9M | 1.4% |
| Vertex recorded | $29.0M | 1.0% |
Vertex Pharmaceuticals Revenue by Segment — Quarterly Trend
Vertex Pharmaceuticals revenue by segment across the last 4 reported quarters, showing how each business line (such as TRIKAFTA/KAFTRIO and ALYFTREK) has evolved quarter over quarter.
| Segment | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 |
|---|---|---|---|---|
| TRIKAFTA/KAFTRIO | $2.4B | — | — | — |
| ALYFTREK | $424.4M | $380.1M | $247.0M | $156.8M |
| Other | $135.9M | — | — | — |
| CASGEVY | $42.9M | — | $16.9M | $30.4M |
| Vertex recorded | $29.0M | — | — | — |
Vertex Pharmaceuticals Annual Revenue by Year
Vertex Pharmaceuticals annual revenue history includes year-by-year totals (for example, 2025 revenue was $12.0B).
Vertex Pharmaceuticals Quarterly Revenue & Net Profit History
Vertex Pharmaceuticals results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $3.0B | +7.8% | $1.0B | 34.5% |
| Q4 FY2025 | $3.2B | +9.5% | $1.2B | 37.3% |
| Q3 FY2025 | $3.1B | +11.0% | $1.1B | 35.2% |
| Q2 FY2025 | $3.0B | +12.1% | $1.0B | 34.8% |
| Q1 FY2025 | $2.8B | +3.0% | $646.3M | 23.3% |
| Q4 FY2024 | $2.9B | +15.7% | $913.0M | 31.4% |
| Q3 FY2024 | $2.8B | +11.6% | $1.0B | 37.7% |
| Q2 FY2024 | $2.6B | +6.1% | $-3.6B | -135.8% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.65B | $2.77B | $2.91B | $2.77B | $2.96B | $3.08B | $3.19B | $2.99B |
| YoY Growth | 6.1% | 11.6% | 15.7% | 3.0% | 12.1% | 11.0% | 9.5% | 7.8% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $20.13B | $22.24B | $22.53B | $22.88B | $24.04B | $24.86B | $25.64B | $26.48B |
| Liabilities | $5.36B | $6.61B | $6.12B | $6.38B | $6.86B | $7.54B | $6.98B | $7.12B |
| Equity | $14.77B | $15.63B | $16.41B | $16.50B | $17.18B | $17.32B | $18.67B | $19.36B |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-3.75B | $1.37B | $584.6M | $818.9M | $1.07B | $1.24B | $498.0M |